MTN-007 was a Phase I follow-up study to RMP-02/MTN-006 that found rectal use of a reduced glycerin formulation of tenofovir gel was safe and acceptable among the 60 men and women who took part in the study at three U.S. sites. Based on results, which were first reported in 2012, researchers proceeded with a Phase II trial of reduced glycerin tenofovir gel, MTN-017. (See also MTN-006 and MTN-017.)
Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex in Early Phase Clinical Trial
3-April-2013
14-March-2012
14-March-2012
See Also
Rectal Microbicides – Fact Sheet
21-Apr-2020
Reduced Glycerin Formulation of Tenofovir Vaginal Gel Safe for Rectal Use
17-May-2012
Rectal Formulation of Tenofovir Gel Found Safe and Acceptable in Early Phase Clinical Study
5-March-2012
Researchers Reformulate Tenofovir Vaginal Gel for Rectal Use
28-February-2011
Promising HIV prevention microbicide tenofovir gel in new trial testing safety of rectal use
13-October-2010